A High-Level Overview of the Regulations Surrounding a Clinical Laboratory and Upcoming Regulatory Challenges for Laboratory Developed Tests
Authors:
- Sarah R DelaneySDSarah R Delaney
- Maria A V WillrichMWMaria A V Willrich
- 7 December 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 52 (4) , 315-328
Abstract
Objective: Regulations for clinical laboratories in the United States are complex. The goal of this review is to improve the clarity of laboratory-developed test (LDT) regulation to facilitate innovation. Methods: A literature and regulation review of current legislation for compliance by U.S. clinical laboratories was performed, and examples of the steps to implement LDTs within compliance with the regulatory environment are shared. Results: Many federal and state jurisdictions are critical to the functionality of a laboratory in addition to upcoming potential promulgation of the Verifying Accurate Leading-Edge IVCT Development Act. Increased regulation, although imperative to maintain consistent, high-standard clinical care, could mean additional costs for developers and healthcare while also hindering innovation. Conclusion: An extensive discussion of proposed regulations for LDTs needs to occur. Laboratory testing requires the sustained use of innovative methods at a cost that will permit continued, timely, uninterrupted high-quality service.Keywords
This publication has 13 references indexed in Scilit:
- CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexesClinical Chemistry and Laboratory Medicine (CCLM), 2018
- Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myelomaClinical Biochemistry, 2018
- Laboratory-Developed Tests: A Legislative and Regulatory ReviewClinical Chemistry, 2017
- The utility of MASS‐FIX to detect and monitor monoclonal proteins in the clinicAmerican Journal of Hematology, 2017
- Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass SpectrometryClinical Chemistry, 2016
- Screening Method for M-Proteins in Serum Using Nanobody Enrichment Coupled to MALDI-TOF Mass SpectrometryClinical Chemistry, 2016
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaThe Lancet Oncology, 2016
- Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation2016
- US Food and Drug Administration Perspectives on Clinical Mass SpectrometryClinical Chemistry, 2016
- International Myeloma Working Group updated criteria for the diagnosis of multiple myelomaThe Lancet Oncology, 2014